Law360, New York (October 14, 2011, 6:57 PM ET) -- The European Commission announced Friday that it had conditionally signed off on Teva Pharmaceutical Industries Ltd.’s $6.8 billion acquisition of Cephalon Inc., after Cephalon agreed to sell its rights to market a generic version of its narcolepsy drug Provigil.
The EU antitrust watchdog said that the merger, conditioned on Cephalon divesting its right to market a generic Provigil in France, would not threaten competition in European markets. Teva said the regulator’s approval was the final step it needed to complete its takeover of Cephalon on Friday....
Teva, Cephalon Win EU Antitrust OK For $6.8B Tie-Up
To view the full article, take a free trial now.
